MA52631A - Compositions et méthodes pour le traitement de la maladie de parkinson - Google Patents

Compositions et méthodes pour le traitement de la maladie de parkinson

Info

Publication number
MA52631A
MA52631A MA052631A MA52631A MA52631A MA 52631 A MA52631 A MA 52631A MA 052631 A MA052631 A MA 052631A MA 52631 A MA52631 A MA 52631A MA 52631 A MA52631 A MA 52631A
Authority
MA
Morocco
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Application number
MA052631A
Other languages
English (en)
Inventor
Adrian Philip Kells
Bernard Ravina
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of MA52631A publication Critical patent/MA52631A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
MA052631A 2018-05-15 2019-05-15 Compositions et méthodes pour le traitement de la maladie de parkinson MA52631A (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862671944P 2018-05-15 2018-05-15
US201862681891P 2018-06-07 2018-06-07
US201862684384P 2018-06-13 2018-06-13
US201862691748P 2018-06-29 2018-06-29
US201862698419P 2018-07-16 2018-07-16
US201862703137P 2018-07-25 2018-07-25
US201862741021P 2018-10-04 2018-10-04
US201862748119P 2018-10-19 2018-10-19
US201862756897P 2018-11-07 2018-11-07
US201962789909P 2019-01-08 2019-01-08
US201962831400P 2019-04-09 2019-04-09

Publications (1)

Publication Number Publication Date
MA52631A true MA52631A (fr) 2021-03-24

Family

ID=67060450

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052631A MA52631A (fr) 2018-05-15 2019-05-15 Compositions et méthodes pour le traitement de la maladie de parkinson

Country Status (13)

Country Link
US (1) US20210198691A1 (fr)
EP (1) EP3794126A1 (fr)
JP (1) JP2021523914A (fr)
KR (1) KR20210019996A (fr)
CN (1) CN112424359A (fr)
AU (1) AU2019268330A1 (fr)
BR (1) BR112020023082A2 (fr)
CA (1) CA3099306A1 (fr)
MA (1) MA52631A (fr)
MX (1) MX2020012077A (fr)
SG (1) SG11202011296VA (fr)
TW (1) TW202012628A (fr)
WO (1) WO2019222328A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
WO2018191450A2 (fr) 2017-04-14 2018-10-18 National Taiwan University Hospital Thérapie génique pour une carence en aadc
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2021007382A1 (fr) * 2019-07-09 2021-01-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de la maladie de parkinson
BR112022016596A2 (pt) 2020-02-21 2022-11-16 Akouos Inc Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano
CN115607684A (zh) * 2021-07-15 2023-01-17 华中科技大学 一种内耳药物纳米载体及其应用
CN116554278A (zh) * 2022-01-30 2023-08-08 上海玮美基因科技有限责任公司 变异型腺相关病毒及其在疾病治疗中的应用

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467096A (en) 1966-04-12 1969-09-16 Ferrell S Horn Multiple hypodermic syringe arrangement
BE786542A (fr) 1971-07-22 1973-01-22 Dow Corning Dispositif d'aspiration permettant d'obtenir des echantillons de cellules
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
US4474569A (en) 1982-06-28 1984-10-02 Denver Surgical Developments, Inc. Antenatal shunt
US5078140A (en) 1986-05-08 1992-01-07 Kwoh Yik S Imaging device - aided robotic stereotaxis system
FR2640638B1 (fr) 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
US5012818A (en) 1989-05-04 1991-05-07 Joishy Suresh K Two in one bone marrow surgical needle
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5199441A (en) 1991-08-20 1993-04-06 Hogle Hugh H Fine needle aspiration biopsy apparatus and method
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
WO1994009838A1 (fr) 1992-11-04 1994-05-11 Denver Biomaterials, Inc. Procede et appareil d'evacuation d'un fluide d'epanchement pleural
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
EP0796339A1 (fr) 1994-12-06 1997-09-24 Targeted Genetics Corporation Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants
EP0727187B1 (fr) 1995-02-15 2003-08-06 Joseph Eldor Aiguille spinale à ouvertures multiples
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
EP0932694A2 (fr) 1996-09-11 1999-08-04 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vecteur de vaa4 et ses utilisations
US5865744A (en) 1996-09-16 1999-02-02 Lemelson; Jerome H. Method and system for delivering therapeutic agents
EP1760151B1 (fr) 1996-11-20 2012-03-21 Crucell Holland B.V. Compositions d'adenovirus pouvant être obtenues au moyen d'un procédé de production et purification amélioré
WO1998027204A2 (fr) 1996-12-18 1998-06-25 Targeted Genetics Corporation Genes d'encapsidation fractionnes de virus adeno-associe (aav) et lignees cellulaires comprenant ces genes utilises pour la production de vecteurs d'aav de recombinaison
US5759179A (en) 1996-12-31 1998-06-02 Johnson & Johnson Medical, Inc. Needle and valve assembly for use with a catheter
NZ333334A (en) 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU9397098A (en) 1997-09-19 1999-04-12 Trustees Of The University Of Pennsylvania, The Methods and cell line useful for production of recombinant adeno-associated viruses
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
EP1064393B1 (fr) 1998-03-20 2004-12-29 The Trustees Of The University Of Pennsylvania Compositions et methodes de production de virus adeno-associes recombines sans auxiliaire
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP1080202B1 (fr) * 1998-05-27 2006-01-25 Avigen, Inc. Apport par la convection de vecteurs viraux adeno-associes (aav) codant pour l'aadc
EP1621626B1 (fr) * 1998-05-27 2009-07-08 Genzyme Corporation Vecteurs AAV pour la fabrication des médicaments pour l'administration amélioré par la convection
GB9817662D0 (en) 1998-08-13 1998-10-07 Crocker Peter J Substance delivery
WO2000024916A1 (fr) 1998-10-27 2000-05-04 Crucell Holland B.V. Production amelioree de vecteurs de virus associes aux adenovirus
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
WO2000075353A1 (fr) 1999-06-02 2000-12-14 Trustees Of The University Of Pennsylvania Compositions et methodes pour la fabrication de virus recombines necessitant des virus auxiliaires
AU1071701A (en) 1999-09-29 2001-04-30 Trustees Of The University Of Pennsylvania, The Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
US6613026B1 (en) 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
US6726659B1 (en) 1999-12-09 2004-04-27 John E. Stocking Catheter assembly having a fenestrated dilator
US6382212B1 (en) 2000-01-18 2002-05-07 Medtronic, Inc. Fenestrated surgical drape with in situ features
US6565572B2 (en) 2000-04-10 2003-05-20 Sdgi Holdings, Inc. Fenestrated surgical screw and method
AU6808001A (en) 2000-05-23 2001-12-03 Neurologix Inc Glutamic acid decarboxylase (gad) based delivery systems
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US6520949B2 (en) 2001-04-02 2003-02-18 Martin St. Germain Method and apparatus for administering fluid to animals subcutaneously
WO2002095006A2 (fr) 2001-05-24 2002-11-28 Genzyme Corporation Vecteurs d'expression specifiques aux muscles
CN103555678B (zh) 2001-11-13 2018-02-09 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US7198951B2 (en) 2001-12-17 2007-04-03 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
WO2005017101A2 (fr) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Virus aviaire adenoassocie (aaav) et ses utilisations
PT1625210E (pt) 2003-05-21 2011-03-15 Genzyme Corp Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
JP2007524386A (ja) 2003-06-19 2007-08-30 アビジェン， インコーポレイテッド 減少した免疫反応性を有するａａｖビリオン、およびその使用
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
ES2478625T3 (es) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8333734B2 (en) 2003-07-03 2012-12-18 Walter A. Zohmann Fenestrated peripheral nerve block needle and method for using the same
US7575572B2 (en) 2003-07-15 2009-08-18 Spinal Generations, Llc Method and device for delivering medicine to bone
ES2874298T3 (es) 2003-09-30 2021-11-04 Univ Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
US7135010B2 (en) 2003-09-30 2006-11-14 Damage Control Surgical Technologies, Inc. Method and apparatus for rapid deployment chest drainage
US7699852B2 (en) 2003-11-19 2010-04-20 Zimmer Spine, Inc. Fenestrated bone tap and method
WO2005056807A2 (fr) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Vecteur viral associe aux adenovirus bovins et leurs utilisations
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
DK2359867T3 (en) 2005-04-07 2015-01-05 Univ Pennsylvania A method for increasing an AAV vector function
WO2006119432A2 (fr) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, clonage, et caracterisation de nouveaux serotypes de virus adeno-associes (avv)
EP1857552A1 (fr) 2006-05-20 2007-11-21 Cargill Incorporated Xylose isomérase thermostable
WO2007046703A2 (fr) 2005-10-20 2007-04-26 Amsterdam Molecular Therapeutics B.V. Vecteurs aav ameliores produits dans des cellules d'insecte
AU2006320611A1 (en) 2005-11-29 2007-06-07 Surgi-Vision, Inc. MRI-guided localization and/or lead placement systems, related methods, devices and computer program products
EP2007795B1 (fr) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Protéines de capsides aav
BRPI0811648A2 (pt) 2007-05-17 2014-11-11 Medgenesis Therapeutix Inc Cateter para administrar um agente a partir de um suprimento para tecido visado de um organismo de mamífero, e, métodos para administrar um agente para tecido visado disposto além de tecido intermediário de um organismo de mamífero, e para administrar um agente a partir de um suprimento para tecido visado disposto além de tecido intermediário de um organismo de mamífero
WO2008145400A2 (fr) 2007-05-31 2008-12-04 Medigene Ag Protéine structurale mutée d'un parvovirus
US8175677B2 (en) 2007-06-07 2012-05-08 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
EP2019143A1 (fr) 2007-07-23 2009-01-28 Genethon Thérapie génique du CNS utilisant l'administration périphérique de vecteurs AAV
US8099150B2 (en) 2007-09-24 2012-01-17 MRI Interventions, Inc. MRI-compatible head fixation frame with cooperating head coil apparatus
US8548569B2 (en) 2007-09-24 2013-10-01 MRI Interventions, Inc. Head fixation assemblies for medical procedures
WO2009042130A2 (fr) 2007-09-24 2009-04-02 Surgivision, Inc. Systèmes et procédés d'intervention médicaux guidés par irm
EP2058401A1 (fr) 2007-10-05 2009-05-13 Genethon Fourniture généralisée de gènes à des motoneurones utilisant l'injection périphérique de vecteurs AAV
WO2009067205A1 (fr) 2007-11-21 2009-05-28 Surgi-Vision, Inc. Procédés, systèmes et programmes informatiques pour le positionnement d'un appareil de guidage par rapport à un patient
EP2315833B8 (fr) 2008-05-20 2015-05-27 Eos Neuroscience, Inc. Vecteurs pour la délivrance de protéines photosensibles et procédés d'utilisation
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
WO2010138263A2 (fr) 2009-05-28 2010-12-02 University Of Massachusetts Nouveaux virus adéno-associés (aav) et leurs utilisations
WO2010148083A2 (fr) 2009-06-16 2010-12-23 Surgivision, Inc. Dispositifs guidés par irm et systèmes d'intervention guidés par irm qui peuvent suivre et générer des visualisations dynamiques des dispositifs presque en temps réel
WO2011008495A2 (fr) 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Formulations d'arginase et procédés
US9163261B2 (en) 2010-02-22 2015-10-20 Koteswara Rao KOLLIPARA Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer
EP2550021A2 (fr) 2010-03-22 2013-01-30 Association Institut de Myologie Procédés d'augmentation de l'efficacité de pénétration d'un vecteur dans un tissu cible
PL2558154T3 (pl) 2010-04-16 2020-11-30 Clearpoint Neuro, Inc. Systemy chirurgiczne MRI zawierające kaniule chirurgiczne kompatybilne z MRI do transferu substancji do i/lub od pacjenta
EP3567106A1 (fr) 2010-04-23 2019-11-13 University of Massachusetts Vecteurs aav de ciblage du système nerveux central et leurs procédés d'utilisation
EP2394667A1 (fr) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
EP2678433B1 (fr) 2011-02-22 2017-05-03 California Institute of Technology Fourniture de protéines au moyen de vecteurs de virus adéno-associés (aav)
US20140024909A1 (en) 2011-02-24 2014-01-23 MRI Interventions, Inc. Mri-guided catheters
US20120295960A1 (en) * 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
EP2739341B1 (fr) 2011-08-01 2021-02-17 Alcyone Lifesciences, Inc. Dispositifs microfluidiques d'administration de médicament
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
US9192393B2 (en) 2012-05-31 2015-11-24 MRI Interventions, Inc. MRI compatible surgical drills and related methods
US9031636B2 (en) 2012-07-19 2015-05-12 MRI Interventions, Inc. MRI-compatible head fixation apparatus
US9498290B2 (en) 2012-07-19 2016-11-22 MRI Interventions, Inc. Surgical navigation devices and methods
US10206693B2 (en) 2012-07-19 2019-02-19 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
US9192446B2 (en) 2012-09-05 2015-11-24 MRI Interventions, Inc. Trajectory guide frame for MRI-guided surgeries
EP2900686B1 (fr) 2012-09-28 2020-06-10 The University of North Carolina At Chapel Hill Vecteurs vaa ciblés sur des oligodendrocytes
WO2014124282A1 (fr) 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Transfert génétique médié par aav amélioré pour thérapies rétiniennes
EP3460049A1 (fr) 2013-02-22 2019-03-27 Genzyme Corporation Procédés de mise en culture de perfusions micro-porteuses et leurs utilisations
US9572928B2 (en) 2013-03-13 2017-02-21 MRI Interventions, Inc. Substance delivery devices, systems and methods
US9498575B2 (en) 2013-03-14 2016-11-22 MRI Interventions, Inc. Substance delivery devices, systems and methods
JP6396988B2 (ja) 2013-03-15 2018-09-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合性ａａｖベクターのための方法および組成物
US9618590B2 (en) 2013-03-15 2017-04-11 MRI Interventions, Inc. Tip assembly for MRI-compatible medical devices and MRI-compatible medical devices incorporating same
TWI500551B (zh) 2013-04-26 2015-09-21 Ful Chee Ent Co Ltd Bicycle quick release structure
WO2014178863A1 (fr) 2013-05-01 2014-11-06 Genzyme Corporation Compositions et procédés pour traiter l'amyotrophie spinale
JP6600624B2 (ja) 2013-05-31 2019-10-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルス変異体及びその使用方法
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
EP3633041A3 (fr) 2013-09-26 2020-07-29 University of Florida Research Foundation, Inc. Bibliothèque de capsides aav combinatoire synthétique pour la thérapie génique ciblée
EP3046500B1 (fr) 2013-10-16 2020-08-26 ClearPoint Neuro, Inc. Système chirurgical de navigation et dispositif associé
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
US10595744B2 (en) 2014-02-14 2020-03-24 MRI Interventions, Inc. Surgical tool-positioning devices and related methods
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
RS62078B1 (sr) 2014-05-02 2021-07-30 Genzyme Corp Aav vektori za gensku terapiju mrežnjače i cns
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
PL3198018T3 (pl) 2014-09-24 2021-07-19 City Of Hope Warianty wektora wirusa związanego z adenowirusami dla wysokiej skuteczności edycji genomu i jego sposoby
US10480011B2 (en) 2014-10-21 2019-11-19 University Of Massachusetts Recombinant AAV variants and uses thereof
CA2966620A1 (fr) * 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Polynucleotides codant pour la dopa decarboxylase et destines au traitement de la maladie de parkinson
JP2018506304A (ja) 2015-02-10 2018-03-08 ジェンザイム・コーポレーション バリアントＲＮＡｉ
US20180135074A1 (en) * 2015-02-19 2018-05-17 University Of Florida Research Foundation, Incorporated Recombinant aav vectors for gene therapy of human hematopoietic disorders
CA2977355A1 (fr) 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methodes et compositions de traitement de maladies oculaires genetiques
US20180216133A1 (en) 2015-07-17 2018-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells
US20190000940A1 (en) * 2015-07-31 2019-01-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
PT3356390T (pt) 2015-09-28 2021-04-21 Univ Florida Métodos e composições para vetores virais que se evadem a anticorpos
WO2017066764A2 (fr) 2015-10-16 2017-04-20 William Marsh Rice University Modification de la région n-terminale des protéines de capsides pour améliorer les propriétés des virus adéno-associés
WO2017083722A1 (fr) 2015-11-11 2017-05-18 Greenberg Kenneth P Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique
US10240145B2 (en) 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
MX2018006840A (es) 2015-12-11 2019-03-28 California Inst Of Techn Focalizacion de peptidos para dirigir virus adenoasociados.
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP2021521852A (ja) * 2018-04-27 2021-08-30 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ａａｄｃウイルスベクターの効力を測定する方法
WO2021154923A2 (fr) * 2020-01-29 2021-08-05 Voyager Therapeutics, Inc. Procédés et systèmes de production de particules d'aav

Also Published As

Publication number Publication date
KR20210019996A (ko) 2021-02-23
US20210198691A1 (en) 2021-07-01
JP2021523914A (ja) 2021-09-09
EP3794126A1 (fr) 2021-03-24
CN112424359A (zh) 2021-02-26
BR112020023082A2 (pt) 2021-02-09
WO2019222328A1 (fr) 2019-11-21
MX2020012077A (es) 2021-03-09
TW202012628A (zh) 2020-04-01
SG11202011296VA (en) 2020-12-30
AU2019268330A1 (en) 2020-11-26
CA3099306A1 (fr) 2019-11-21

Similar Documents

Publication Publication Date Title
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA54132A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA51738A (fr) Composés pour le traitement de la douleur
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité